Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Other cardiovascular risk factors

Cardiovascular risk arises from interactions among exposures, individual characteristics, and diseases that alter the function of blood vessels and the heart. Alongside blood pressure, lipoproteins, and glucose metabolism, smoking, chronic kidney disease, and sleep-related breathing disorders play a significant role. Their contribution is not limited to increasing the likelihood of plaque formation: it also encompasses thrombosis, myocardial remodeling, arrhythmias, and disturbances in blood pressure regulation.

These factors differ in nature. Tobacco is a toxic exposure often sustained by addiction; kidney disease is an organ disorder that can both exacerbate and be affected by cardiovascular damage; sleep apnea is an intermittent breathing disorder during sleep, with heterogeneous severity and effects. Effective prevention requires recognizing these differences, because a risk measure or treatment cannot automatically be transferred from one condition to another.

Exposures and mechanisms of injury

The relationship between smoking and cardiovascular disease involves combustion products, particulate matter, and nicotine. Oxidative stress, endothelial dysfunction, and platelet activation may be accompanied by increased myocardial oxygen demand and reduced oxygen availability. Cigarette count does not describe a linear relationship with risk: even low consumption entails substantial cardiovascular harm, and involuntary exposure has its own significance.

In kidney dysfunction, the effects of hypertension, sodium retention, inflammation, and metabolic abnormalities accumulate. Reduced glomerular filtration and urinary albumin loss provide different information. A patient may have substantial albuminuria with preserved filtration, or reduced filtration with modest albuminuria; both profiles require clinical interpretation and may affect cardiovascular prognosis.

Nocturnal airway obstructions cause intermittent hypoxia, arousals, and fluctuations in intrathoracic pressure. Autonomic activation may persist beyond individual episodes and contribute to hypertension and rhythm instability. However, the number of respiratory events does not capture all relevant information: the depth and duration of oxygen desaturations, symptoms, obesity, and preexisting heart disease help establish the disorder's clinical significance.

Exposures may add to one another through shared pathways. A smoker with kidney disease and sleep apnea may simultaneously have endothelial dysfunction, poorly controlled blood pressure, and susceptibility to arrhythmias. This does not justify adding percentages from different studies or attributing every finding to a single cause. Instead, assessment must link the mechanisms to diseases that have actually been documented.

Medical history and clinical recognition

History-taking should bring to light information that may not be volunteered spontaneously. Tobacco assessment covers current and past use, products other than cigarettes, secondhand exposure, and previous attempts to quit. For sleep, snoring, breathing pauses witnessed by a partner, awakening with a choking sensation, and sleepiness while driving may be decisive. A nonjudgmental discussion improves the reliability of information and helps identify barriers to care.

The renal history includes previous test results, episodes of acute kidney injury, diabetes, hypertension, systemic diseases, and potentially nephrotoxic medications. A single recent creatinine result does not establish how long the problem has been present. Reviewing its course helps distinguish a stable condition from rapidly declining function requiring prompt investigation.

The examination integrates blood pressure, volume status, and vascular findings. Edema, weight changes, peripheral pulses, heart rate, and rhythm may point to existing complications; anthropometry and airway characteristics help evaluate suspected sleep-disordered breathing. The absence of obvious findings does not rule out significant exposures or early disease, while dyspnea, chest pain, and neurological deficits must be assessed according to their urgency.

Problem-directed investigations

When assessing chronic kidney disease and cardiovascular risk, serum creatinine with estimated glomerular filtration rate and the urine albumin-to-creatinine ratio are complementary measurements. Persistence of the abnormalities, urine sediment, and appropriate etiological investigations complete the diagnostic workup. It is insufficient to interpret a value as “normal for age” without considering injury, its course, and treatment implications.

Suspected obstructive sleep apnea is confirmed with respiratory monitoring or polysomnography appropriate to the patient. Questionnaires help estimate the probability but do not replace measurement of respiratory events. Significant heart disease, hypoventilation, other comorbidities, or inconclusive home testing may warrant a more comprehensive sleep study.

For tobacco use, exposure and dependence are assessed primarily through clinical evaluation. Exhaled carbon monoxide and nicotine metabolites may be useful in selected care pathways, subject to specific limitations. However, no test can certify the absence of smoking-related damage: a normal ECG or echocardiogram does not make continued exposure safe.

Determining risk and target-organ damage

Global cardiovascular risk models include some determinants and omit others. Smoking features in many algorithms, while kidney function and albuminuria are incorporated differently; sleep characteristics are not ordinarily converted into an additional coefficient. The population, outcomes, and limitations of the model must be respected, particularly when existing conditions already confer high risk.

Investigation of subclinical damage is useful if it informs a specific decision. ECG, echocardiography, ambulatory blood pressure monitoring, and vascular investigations are selected according to symptoms, findings, and likelihood of disease. Ordering numerous tests without a clinical question may yield incidental findings and subsequent procedures without demonstrated benefit. Conversely, well-founded suspicion must not be dismissed as merely age-related or attributable to comorbidities.

Atherosclerotic risk must be distinguished from the risk of heart failure or arrhythmic death. In advanced kidney disease, for example, a substantial proportion of cardiovascular mortality results from processes that cannot be corrected by LDL lowering alone. This distinction does not diminish the value of lipid-lowering therapy when indicated; it explains why volume management, blood pressure control, and attention to electrolytes and cardiac structure are also necessary.

Treatment and integrated prevention

Smoking cessation combines behavioral support with medication when appropriate. Dependence calls for active treatment and ongoing support even after a relapse. Reducing consumption may be a step in the process, but the cardiovascular goal is to end exposure to combustion, while also protecting household members from secondhand smoke.

Cardiorenal protection includes interventions targeting blood pressure, albuminuria, and lipoproteins, alongside treatments that slow kidney disease progression and reduce heart failure in defined populations. Renin–angiotensin system inhibitors, SGLT2 inhibitors, and other options require precise indications and monitoring. A modest initial hemodynamic change in filtration does not necessarily indicate toxicity; hypotension, volume depletion, and significant abnormalities must instead be recognized and managed.

Treatment of sleep apnea aims to control obstruction, symptoms, and clinical consequences. Positive airway pressure, weight management, and selected alternatives have varying effectiveness according to anatomy, severity, and adherence. Improved breathing and reduced sleepiness alone do not demonstrate a reduction in cardiovascular events: studies of these outcomes must be interpreted separately.

Care for coexisting risk factors continues throughout. Treating sleep apnea does not replace necessary antihypertensive medications; quitting smoking does not remove the indication for secondary prevention after a myocardial infarction; slowing kidney disease does not resolve symptomatic coronary stenosis. Coordinating interventions reduces omissions, duplication, and barriers to adherence.

Prognosis, complications, and follow-up

Prognosis depends on the intensity and duration of exposure, preexisting disease, and response to treatment. After smoking cessation, risk decreases over time, with different timelines for different outcomes; in kidney disease, both renal and cardiac trajectories must be monitored. In sleep apnea, symptom response and control of respiratory events should be documented during actual use of treatment.

Complications include ischemic events and heart failure, arrhythmias, declining kidney function, and loss of independence. Sleepiness adds a risk of accidents, while dependence and relapse may perpetuate tobacco exposure even after a major event. Follow-up should therefore assess clinical outcomes and address the practical barriers to sustaining benefits.

References
  1. Visseren FLJ et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42(34):3227–3337.
  2. McEvoy JW et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal. 2024;45(38):3912–4018.
  3. Mach F et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2025;46(42):4359–4378.
  4. Ndumele CE et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606–1635.
  5. World Health Organization. WHO clinical treatment guideline for tobacco cessation in adults. World Health Organization, Geneva. 2024.
  6. Hackshaw A et al. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ. 2018;360:j5855.
  7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4S):S117–S314.
  8. Matsushita K et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nature Reviews Nephrology. 2022;18(11):696–707.
  9. Kapur VK et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine. 2017;13(3):479–504.
  10. Patil SP et al. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine. 2019;15(2):335–343.
  11. McEvoy RD et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. The New England Journal of Medicine. 2016;375(10):919–931.
  12. Azarbarzin A et al. The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study. European Heart Journal. 2019;40(14):1149–1157.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.